HIF-2α Inhibitor Scaffolds for Selective Cancer and Inflammation Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for inhibitors of hypoxia-inducible factor-2α (HIF-2α) to address poor clinical outcomes in various cancers and inflammatory disorders, as HIF-2α overexpression is associated with these conditions.
Innovation Solution
Development of tetralin and tetrahydroquinoline compounds that inhibit HIF-2α activity, represented by Formula (I), which can be administered to treat diseases mediated by HIF-2α, including cancer, inflammation, and autoimmune disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If HIF-2α inhibitors are developed to treat cancer and inflammatory disorders, then therapeutic effectiveness is improved, but drug selectivity and pharmacokinetic properties may be compromised
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features at particular positions to achieve selective HIF-2α inhibition. The core tetralin or tetrahydroquinoline structure with specific substituents (R1-R6 groups) creates localized interactions with the HIF-2α protein binding site, enabling selective inhibition while maintaining therapeutic effectiveness.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters such as substituent types, positions, and configurations on the core structure to optimize both selectivity and pharmacokinetic properties. By changing molecular weight, lipophilicity, and other physicochemical parameters through substituent modification, the compounds achieve improved drug-like properties while maintaining HIF-2α inhibitory activity.
2Adaptability or versatility
If broad-spectrum HIF inhibitors are used to treat multiple diseases, then versatility is improved, but off-target effects and harmful factors increase
Solution Approach 1:
The patent applies inversion by targeting HIF-2α specifically rather than using broad-spectrum HIF inhibitors that affect multiple HIF isoforms. By inverting the approach from non-selective to selective inhibition, the compounds can treat multiple HIF-2α-mediated diseases (cancer, inflammatory disorders, metabolic disorders) without the off-target effects associated with broad-spectrum inhibitors.
3Adaptability or versatility
If complex molecular structures are designed to improve selectivity, then drug selectivity is improved, but manufacturing complexity and cost increase
Solution Approach 1:
The patent applies segmentation by dividing the molecule into a core structure (tetralin or tetrahydroquinoline) and variable substituent groups (R1-R6). This modular design allows the core structure to be synthesized once and then combined with different substituents to create multiple analogs with varying selectivity profiles, simplifying manufacturing compared to designing entirely complex structures for each compound.
Data Source
AI summary
Compounds that inhibit HIF-2α, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2α.